Tear protein biomarkers of refractive surgery pain

屈光手术疼痛的泪液蛋白生物标志物

• 批准号: 10786192
• 负责人: SUE A AICHER
• 金额: $ 88.37万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10786192
• 关键词: Ablation; Acute Pain; Age; Algorithms; American; Bathing; Biological; Biological Assay; Biological Markers; Biometry; Categories; Clinical; Collection; Consensus; Cornea; Corneal Injury; Corneal pain; Detection; Development; Diagnostic; Disease; Disease Progression; Excision; Eye; Eye diseases; Feeling suicidal; Future; Goals; Hour; In Situ; Individual; Knowledge; Lasers; Link; Lipids; Liquid substance; Mass Spectrum Analysis; Measures; Mental Health; Methods; Morbidity - disease rate; Nerve; Nociception; Non-Steroidal Anti-Inflammatory Agents; Normal Range; Numeric Rating Scale; Operative Surgical Procedures; Ophthalmologic Surgical Procedures; Opioid; Oral; Outcome; Pain; Pain Measurement; Pain management; Participant; Patients; Persistent pain; Phase; Photorefractive Keratectomy; Population; Postoperative Pain; Probability; Procedures; Prognostic Marker; Protein Analysis; Proteins; Proteomics; Quality of life; Refractive Errors; Reporting; Reproducibility; Risk; Sampling; Sensory Nerve Endings; Smoking Status; Source; Suicide; Surface; Therapeutic; Treatment Efficacy; United States; Validation; Variant; Vision; Visit; Vulnerable Populations; Water; Work; analytical method; antinociception; biomarker signature; biomarker validation; combat; corneal ablation; corneal epithelium; diagnostic biomarker; experience; eye dryness; improved; keratomileusis; ocular pain; pain reduction; pain score; patient population; patient screening; patient stratification; predictive marker; prognostic; prognostication; protein biomarkers; recruit; resilience; response; sex; surgical pain; tear proteins

PROJECT SUMMARY Photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) are surgical procedures used to correct refractive errors, with approximately 600,000 surgeries performed in the United States each year. A proportion (10 - 20%) of individuals develop persistent ocular pain after refractive surgery, which is a source of tremendous morbidity, limiting the ability to work, impacting mental health, and leading to suicidal ideation in severe cases. We hypothesize that proteins in the tear fluid modulate corneal nerve function, increasing the risk of and contributing to persistent pain after refractive surgery. As such, our studies will use proteomic analysis of tear fluid after surgery to identify diagnostic biomarkers for persistent ocular pain. We will also examine tear proteins prior to surgery in an effort to identify prognostic biomarkers that predict which individuals are likely to develop persistent pain after surgery. R33 Phase studies will use an alternative proteomics platform for analytical validation, and an additional new patient population for clinical validation. This knowledge can lead to better preventative and therapeutic algorithms to combat this debilitating condition and thus improve quality of life and decrease patient suffering.

项目总结